OncoMatch/Clinical Trials/NCT04440267
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Is NCT04440267 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for acute leukemia of ambiguous lineage.
Treatment: vincristine · daunorubicin · cyclophosphamide · L-Asparaginase · prednisone · mercaptopurine · methotrexate · dexamethasone · Tyrosine kinase inhibitor — In this prospective, single arm, open label, clinical trial, a total of 50 acute leukemia of ambiguous lineage patients will be enrolled. Patients will receive acute lymphoblastic leukemia (ALL) -based chemotherapy and are permitted to receive allogeneic hematopoietic stem cell transplantation (HSCT) after CR . Otherwise, they will finish the consolidation chemotherapy. Patients with t(9;22) will receive chemotherapy combined with tyrosine kinase inhibitors. The purpose of current study is to evaluate the clinical efficacy of ALL-based chemotherapy，effect of genetic abnormality and minimal residual disease (MRD) on prognosis in patients with acute leukemia of ambiguous lineage.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Performance status
ECOG 2–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Kidney function
Creatinine ≤ 1.5 x ULN
Liver function
Total bilirubin ≤ 1.5 x ULN; SGOT and SGPT ≤ 2.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related
Cardiac function
ejection fraction ≥ 45% on MUGA scan
Adequate end organ function as defined by: Total bilirubin ≤ 1.5 x ULN; SGOT and SGPT ≤ 2.5 x ULN; Creatinine ≤ 1.5 x ULN; Serum amylase and lipase ≤ 1.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related; Patients must have adequate cardiac function (ejection fraction ≥ 45 % on Multiple Gated Acquisition (MUGA) scan).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04440267 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify